IP Validates Novelty and Breadth of Sagittari™ Platform 

May 24, 2022
PanTher Therapeutics Stent + Dan Quote Card -05-2022 DWfinal.jpg

PanTher announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher, has been issued by the USPTO. The patent increases the potential applicability of PanTher’s proprietary Sagittari™ treatment platform, which focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents to attack cancer at the source. PanTher also announced Dan Wildman as a strategic advisor. A seasoned executive with more than 35 years of experience in the MedTech industry, Mr. Wildman previously led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide president of Depuy Synthes Spine and Ethicon Biosurgery. Mr. Wildman will apply his decades of experience to advancing the clinical development program for PTM-101 and selecting and prioritizing other Sagittari™ platform product candidates.

PanTher named "Emerging MedTech of the Year" at NEVYs

December 3, 2021
PanTher; Winner Emerging MedTech Company of the Year.png

Last night the New England Venture Capital Association (NEVCA) honored the winners of its ninth annual NEVY Awards, recognizing and celebrating the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem — the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. We’re honored to receive the recognition for “Emerging MedTech Company of the Year” among Boston’s top startups and late-stage companies at the 9th annual NEVY Awards! 💥A big thank you to the New England Venture Capital Association and their Academy members for the recognition and a shoutout to our team 🦸🏻‍♀️🦹 that made this win possible.

PanTher Doses First Two Patients in Phase 1 Trial of PTM-101 

October 6, 2021
PanTher Therapeutics First Patients Dosed Quote Card - Oct-05-2021 v3 web.png

PanTher announced today the dosing of the first two patients in its Phase 1 linical trial of PTM-101 for the treatment of pancreatic cancer. This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma. “Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors,” said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. “We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer.

PanTher Receives Approval to Initiate Phase1 Trial in Australia

August 4, 2021
PanTher CMO and CAB Quote Card Marc Pipas 2.png

PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.

PanTher Closes Oversubscribed $5.4M Series A Round

June 17, 2021
Twitter V2.jpg

PanTher announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M. Proceeds from the funding will go toward the company’s first-in-human clinical trial. The company also announced today the additions of Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, to its board of directors. “PanTher represents a truly new therapeutic modality that has the potential to change the way we deliver lifesaving drugs to tumors,” noted Zaveri.

PanTher starred in documentary on Cambridge biotech industry

August 5, 2020

The PanTher Therapeutics team was included in a new documentary about the transformation of an unassuming neighborhood into the innovation and biotechnology ‘capital of the world’. Once shuttered manufacturing plants and vacant parking lots are now home to hundreds of biotechnology companies, nearly all the world’s major pharmaceutical firms, millions of square feet of lab space, tech giants from Google and Microsoft to Facebook and Twitter, and countless startups. And revolutionary, lifesaving therapies and drugs developed here have affected the lives of billions of people across the globe. Join us for the inside story of the rise of one of the world’s most extraordinary innovation clusters – a community now on the front lines of the battle against Covid-19.

PanTher founders honored by National Pancreas Foundation

November 13, 2019

PanTher founders Laura Indolfi, David Ting and Elazer Edelman received the “Visions of Hope Award” from the Massachusetts Chapter of The National Pancreas Foundation at the chapter’s “Party for a Cure – Boston Gala.”  The event, which raised over $230,000 to support the NPF in research and its mission to find cures for all pancreatic diseases, was held at The Harvard Club located in Back Bay, Boston.

PanTher featured on Mass General Brigham’s Innovation Blog

September 3, 2019

PanTher founder Dr. David Ting, MD was featured in the Mass General Brigham’s Innovation Blog as part of a series about companies that are Getting Great Science to Market.  “I think there are certain cancers that this local delivery approach is highly relevant for,” says Ting. “This includes pancreas cancer, esophageal cancer and potentially mesothelioma—the ones we can’t get drugs into very well.”

PanThers CEO to speak at MassBio 2019 Annual Meeting

March 28, 2019

Massachusetts is the epicenter of startup creation for biotech, but it's not always easy to go from research to commercialization. Come hear founders and industry leaders on the panel "Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies" offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. PanTher CEO Laura Indolfi will be one of the panelists for this illuminating discussion hosted by the Massachusetts Biotechnology Council.

PanTher Featured on STAT Startup Spotlight

December 14, 2018

PanTher was featured on the STAT Startup Spotlight in December. Kate Sheridan provided an overview of the company technology and its status highlighting the interest of large pharma companies into the disruptive technology of our early-stage start-up. "Wherever there has been a stage for biotech entrepreneurs this fall, Laura Indolfi has appeared. And wherever she is, major pharmaceutical companies have been, too. Indolfi’s company, Cambridge, Mass.-based PanTher Therapeutics, has already received awards linked to Bristol-Myers Squibb and Johnson & Johnson. And on Tuesday, she competed for — and won — one of Amgen’s Golden Tickets — a one-year pass into LabCentral, the noted Cambridge lab-sharing space where PanTher is already headquartered."

PanTher announces agreement with MD Anderson Cancer Center and appointment of senior clinical advisor

October 16, 2018

PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an agreement with The University of Texas MD Anderson Cancer Center and the appointment of a new senior clinical advisor. The collaboration will support preclinical testing of PanTher’s lead product for pancreatic cancer, PTM-101, and is intended to demonstrate readiness for future human clinical trials.

MLSC & Takeda select PanTher's CEO for MassNextGen

June 20, 2018
Mass Next Gen.png

Laura Indolfi was named one of the five winners of the Massachusetts Life Sciences Center  (MLSC) Initiative for Women Entrepreneurs inaugural awards to support women in early-stage life sciences companies. Lt. Governor Karyn Polito announced the 2018 winners for the MLSC Massachusetts Next Generation Initiative (MassNextGen), a competitive program to support women entrepreneurs in early-stage life sciences companies. The public-private partnership, a five-year, $1.1 million commitment, focuses on empowering women and diversity in the next generation of life sciences entrepreneurs. Five women-led companies were selected as awardees through the MassNextGen program. Awardees represent a wide range of applications to improve human health. All five companies will receive access to a network of executive coaches for a year. 

PanTher's CEO to speak at "How to advance in Biotech"

June 15, 2017

Drug development relies on years of experience across the industry and exposure to multiple upstream and downstream elements in order to be prepared for the challenges in our unique field. If you're a young person working in drug or device development, what are the roles that will give you a broad set of experiences to prepare you for an eventual CEO role? Join us as we will discuss what needs to be done, and where you should put your energy today to be a leader in the field tomorrow. Hear from experts across the industry, from the investors who know what they're looking for when it comes to biotech leadership, the experienced CEO's who know what it takes, and some of the young people on the front lines of successful biotech startups. 

TEDMED Blog: The Hopeful Future of Precision Medicine

October 21, 2016

In 2015, President Obama funded the Precision Medicine Initiative to ensure that researchers could focus on creating efficient and effective ways to integrate more personalized treatment plans into the current healthcare and medical system. This year, we’re excited to be among some of the front-runners in the precision medicine movement on the TEDMED stage! Read about our vision of Precision Medicine to catalyze cancer research on the TEDMED Blog. 

Bristol-Myers Squibb awards PanTher with 'Golden Ticket'

September 20, 2016

Bristol-Myers Squibb Company and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher is one of the winners of Bristol-Myers Squibb’s Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for “Golden Tickets,” which underwrite the cost of one lab bench for one year in LabCentral’s Kendall Square facility. 

PanTher will be at TEDMED in The Hive Program

July 14, 2016

PanTher is delighted to announce that we are among the 25 entrepreneurs and their organizations that have been selected for The TEDMED 2016 Hive Program. The Hive entrepreneurs will join the TEDMED stage program in a special session titled Audacious. TEDMED curates extraordinary people and ideas from all disciplines in pursuit of unexpected connections – to accelerate innovation in health and medicine.

PanTher CEO interviewed for Fast Company

March16, 2016

The pancreas is located in the middle of a person’s belly, surrounded by other vital organs like the liver and stomach. This both makes it extremely hard for surgeons to remove the tumor and easier for it to metastasize and spread. Chemotherapy–which sends toxic drugs throughout the body to reach the tumor site–is still often the only option, and it’s not even very effective because pancreatic tumors have few blood vessels to take up the drugs. “To me, it seems very counterintuitive to have a whole body treatment to target a specific organ,” says CEO Dr. Laura Indolfi.

PanTher’s revolutionary approach featured in Inc.

March 11, 2016

By the time pancreatic cancer is diagnosed, the tumors often are too large to be surgically removed. Doctors use chemotherapy to try to shrink them, but because the pancreatic tumor doesn't have that many blood vessels, the drugs don't often reach the tumor in the desired concentration.  Biomedical engineer Dr. Laura Indolfi envisions a drug-infused bandage that can be wrapped around a tumor to solve this problem.  "A lot of money has been spent, and a lot of research done, to find a new powerful agent for pancreatic cancer. But there aren't enough blood vessels inside. It's wrong for this type of tumor. The drug will go everywhere else."

PanTher CEO featured in Fortune magazine

February 12, 2016

PanTher founder and CEO Laura Indolfi was interviewed by Fortune’s Adam Lashinsky for an article in the Tech Data Sheet titled “An entrepreneur with a novel approach to fighting cancer.” The article previewed Dr. Indolfi’s upcoming presentation at TED in Vancouver, and highlighted the vision behind PanTher Therapeutics and the unique approach the company is taking to fighting solid tumors.

PanTher's CEO, Dr. Laura Indolfi, named a TED Fellow

December 8, 2015

Laura Indolfi, co-founder & CEO of PanTher Therapeutics has been selected as a TED Fellow, joining a class of 21 change-makers from around the world who will share their ideas worth spreading from the TED stage this February in Vancouver. The TED Fellows program brings together young innovators from around the world and across disciplines, who display both outstanding achievement and exemplary character, to ignite their careers.

PanTher selected to participate in MassCONNECT

October 27, 2015

MassCONNECT, the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences industry, has picked PanTher to participate in the 4th cycle of his program. Sponsored by Boehringer Ingelheim and Nixon Peabody LLP, the mentoring will take place in the offices of MassBio.